Chemokine receptor CCR5 is not required for development of experimental autoimmune gastritis

Clinical Immunology

Volumn 109, Issue 2, 2003, Pages 238-247

  Field, Judith ^a   Marshall, Aiden C J ^b   Hertzog, Paul J ^a   Wells, Timothy N ^c   Alderuccio, Frank ^a   Toh, Ban Hock ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

CCR5; Chemokine; Chemokine antagonist; Experimental autoimmune gastritis

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ANALYSIS; GASTRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYMECTOMY;

EID: 0242270665     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00225-0     Document Type: Article

References (42)

1. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs. Science. 286:1999;2098-2102.
2. Ward S.G., Bacon K., Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity. 9:1998;1-11.
3. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:1998;436-445.
4. Adams D.H., Lloyd A.R. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 349:1997;490-495.
5. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today. 19:1998;568-574.
6. Schrum S., Probst P., Fleischer B., Zipfel P.F. Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J. Immunol. 157:1996;3598-3604.
7. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.-M. CCR5 is characteristic of Th1 lymphocytes. Nature 391. 1998;344-345.
8. Toh B.H., van Driel I.R., Gleeson P.A. Pernicious anemia. N. Engl. J. Med. 337:1997;1441-1448.
9. Fukuma K., Sakaguchi S., Kuribayashi K., Chen W.L., Morishita R., Sekita K., Uchino H., Masuda T. Immunologic and clinical studies on murine experimental autoimmune gastritis induced by neonatal thymectomy. Gastroenterology. 94:1988;274-283.
10. Alderuccio F., Toh B.H. Immunopathology of autoimmune gastritis: lessons from mouse models. Histol. Histopathol. 15:2000;869-879.
11. Alderuccio F., Toh B.H. Spontaneous autoimmune gastritis in C3H/He mice: a new mouse model for gastric autoimmunity. Am. J. Pathol. 153:1998;1311-1318.
12. Biondo M., Nasa Z., Marshall A., Toh B.H., Alderuccio F. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J. Immunol. 166:2001;2090-2099.
13. Toh B.H., Sentry J.W., Alderuccio F. The causative H+/K+ ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol. Today. 21:2000;348-354.
14. Martinelli T.M., van Driel I.R., Alderuccio F., Gleeson P.A., Toh B.H. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology. 110:1996;1791-1802.
15. Judd L.M., Gleeson P.A., Toh B.H., van Driel I.R. Autoimmune gastritis results in disruption of gastric epithelial cell development. Am. J. Physiol. 277:1999;G209-218.
16. Barrett S.P., Gleeson P.A., de Silva H., Toh B.H., van Driel I.R. Interferon-gamma is required during the initiation of an organ-specific autoimmune disease. Eur. J. Immunol. 26:1996;1652-1655.
17. Suri-Payer E., Amar A.Z., McHugh R., Natarajan K., Margulies D.H., Shevach E.M. Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur. J. Immunol. 29:1999;669-677.
18. Alderuccio F., Gleeson P.A., Berzins S.P., Martin M., Van Driel I.R., Toh B.H. Expression of the gastric H/K-ATPase alpha-subunit in the thymus may explain the dominant role of the beta-subunit in the pathogenesis of autoimmune gastritis. Autoimmunity. 25:1997;167-175.
19. Alderuccio F., Toh B.H., Tan S.S., Gleeson P.A., van Driel I.R. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J. Exp. Med. 178:1993;419-426.
20. Andres P.G., Beck P.L., Mizoguchi E., Mizoguchi A., Bhan A.K., Dawson T., Kuziel W.A., Maeda N., MacDermott R.P., Podolsky D.K., Reinecker H.C. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte- associated Th2-type immune response in the intestine. J. Immunol. 164:2000;6303-6312.
21. Glass W.G., Liu M.T., Kuziel W.A., Lane T.E. Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotrpoic coronavirus. Virology. 288:2001;8-17.
22. Sato N., Kuziel W.A., Melby P.C., Reddick R.L., Kostecki V., Zhao W., Maeda N., Ahuja S.K., Ahuja S.S. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J. Immunol. 163:1999;5519-5525.
23. Zhou Y., Kurihara T., Ryseck R.P., Yang Y., Ryan C., Loy J., Warr G., Bravo R. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:1998;4018-4025.
24. Plater-Zyberk C., Hoogewerf A.J., Proudfoot A.E., Power C.A., Wells T.N. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57:1997;117-120.
25. Alderuccio F., Sentry J.W., Marshall A.C.J., Biondo M., Toh B.-H. Animal models of human disease: experimental autoimmune gastritis - a model for autoimmune gastritis and pernicious anemia. Clin.Immunol. 102:2002;48-58.
26. Bird J.E., Giancarli M.R., Kurihara T., Kowala M.C., Valentine M.T., Gitlitz P.H., Pandya D.G., French M.H., Durham S.K. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int. 57:2000;129-136.
27. Lukacs N.W., Oliveira S.H., Hogaboam C.M. Chemokines and asthma: redundancy of function or a coordinated effort? J. Clin. Invest. 104:1999;995-999.
28. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol. Today. 20:1999;254-255.
29. Mack M., Cihak J., Simonis C., Luckow B., Proudfoot A.E., Plachy J., Bruhl H., Frink M., Anders H.J., Vielhauer V., Pfirstinger J., Stangassinger M., Schlondorff D. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:2001;4697-4704.
30. Cameron M.J., Arreaza G.A., Grattan M., Meagher C., Sharif S., Burdick M.D., Strieter R.M., Cook D.N., Delovitch T.L. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J. Immunol. 165:2000;1102-1110.
31. Shimada A., Morimoto J., Kodama K., Suzuki R., Oikawa Y., Funae O., Kasuga A., Saruta T., Narumi S. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care. 24:2001;510-515.
32. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A.E., Moser B., Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:1998;746-754.
33. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., Feldmann M., Maini R.N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43:2000;38-47.
34. Karpus W.J., Ransohoff R.M. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161:1998;2667-2671.
35. Izikson L., Klein R.S., Luster A.D., Weiner H.L. Targeting monocyte recruitment in CNS autoimmune disease. Clin. Immunol. 103:2002;125-131.
36. McMahon E.J., Cook D.N., Suzuki K., Matsushima G.K. Absence of macrophage-inflammatory protein-1alpha delays central nervous system demyelination in the presence of an intact blood-brain barrier. J. Immunol. 167:2001;2964-2971.
37. Godessart N., Kunkel S.L. Chemokines in autoimmune disease. Curr. Opin. Immunol. 13:2001;670-675.
38. Tsukahara T., Makino Y., Fujii T., Ogawa M., Saisho H., Hamano Y., Ueda S., Akikusa B., Danoff T.M. Role of RANTES in the development of autoimmune tissue injuries in MRL-Fas lpr mice. Clin. Immunol. 103:2002;89-97.
39. Youssef S., Wildbaum G., Maor G., Lanir N., Gour-Lavie A., Grabie N., Karin N. Long-lasting protective immunity to experiemental autoimmune encephalomyelitis following vaccination with naked DNA encoding CC chemokines. J. Immunol. 161:1998;3870-3879.
40. Youssef S., Maor G., Wildbaum G., Grabie N., Gour-Lavie A., Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106:2000;361-371.
41. Karpus W.J., Lukacs N.W., McRae B.L., Strieter R.M., Kunkel S.L., Miller S.D. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155:1995;5003-5010.
42. Tran E.H., Kuziel W.A., Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory-1alpha or its CCR5 receptor. Eur. J. Immunol. 30:2000;1410-1415.